Etomoxir Sodium Salt Promotes Imidazole Ketone Erastin-Induced Myeloid-Derived Suppressor Cell Ferroptosis and Enhances Cancer Therapy
Biology · 19.11.2024 · 13 (11) · 949
DOI: 10.3390/biology13110949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology, online erschienen am 19.11.2024. Verfasst von Nada Mohamady Farouk Abdalsalam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biote…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Although ferroptosis inducers trigger ferroptotic tumor cells and immune cells in the tumor microenvironment (TME), imidazole ketone erastin (IKE)’s induction of ferroptosis shows no effect on tumor growth in immunocompetent tumor-bearing mice due to the presence of myeloid-derived suppressor cells (MDSCs). Treatment of the carnitine palmitoyltransferase 1a (CPT1A)-specific inhibitor decreases the immunosuppressive function of MDSCs and enhances ferroptotic inducer-initiated tumor cell ferroptosis. However, whether blocking CPT1A could enhance IKE-induced MDSC ferroptosis and thereby inhibit tumor growth is still unclear. Here, we report that a CPT1A-specific inhibitor, etomoxir sodium salt (Eto), and IKE combined treatment increased MDSC ferroptosis. Interestingly, the combination treatment of Eto and IKE blocked MDSCs’ immunosuppressive function and accumulation by downregulating the expression of SLC7A11, GPX4, and ARG1 while promoting T-cell proliferation and infiltration into tumor tissues to enhance cancer therapy. These data provide a rationale for the combination therapy of a specific CPT1A inhibitor, Eto, with IKE in clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy o…
- University of Chinese Academy of Sciences, Beijing 100864, China.
ORCID-Profile: Dehong Yan
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Basic Science Research Project
- Shenzhen Medical Research Fund
- Futian Healthcare Research Project
- Animal Facilities of the Shenzhen Institute of Advanced Technology (SIAT)
- National Key R&D Program of China
Zitieren
APA
Mohamady Farouk Abdalsalam, N., Liang, Z., Kashaf Tariq, H., Ibrahim, A., Li, R., Wan, X., & Yan, D. (2024). Etomoxir Sodium Salt Promotes Imidazole Ketone Erastin-Induced Myeloid-Derived Suppressor Cell Ferroptosis and Enhances Cancer Therapy. Biology, 13(11), 949. https://doi.org/10.3390/biology13110949
Vancouver
Mohamady Farouk Abdalsalam N, Liang Z, Kashaf Tariq H, Ibrahim A, Li R, Wan X, et al. Etomoxir Sodium Salt Promotes Imidazole Ketone Erastin-Induced Myeloid-Derived Suppressor Cell Ferroptosis and Enhances Cancer Therapy. Biology. 2024;13(11):949. doi:10.3390/biology13110949
BibTeX
@article{MohamadyFaroukAbdalsalam2024,
author = {Mohamady Farouk Abdalsalam, Nada and Liang, Zihao and Kashaf Tariq, Hafiza and Ibrahim, Abdulrahman and Li, Rong and Wan, Xiaochun and Yan, Dehong},
title = {Etomoxir Sodium Salt Promotes Imidazole Ketone Erastin-Induced Myeloid-Derived Suppressor Cell Ferroptosis and Enhances Cancer Therapy},
journal = {Biology},
year = {2024},
volume = {13},
number = {11},
pages = {949},
doi = {10.3390/biology13110949}
}
EUVIMED